Upfront Low-Dose Radiation Improves Advanced SCLC Outcomes

Adding low-dose radiation to the current standard first-line treatment, durvalumab plus etoposide-platinum chemotherapy, appears to improve survival outcomes in patients with extensive-stage small cell lung cancer , suggested new findings from a small, single-arm study.

The latest data, which included a small cohort of 30 patients, revealed that adding low-dose radiation to the standard first-line therapy led to a higher median progression-free survival of 8.3 months and extended median overall survival beyond the study follow-up period of 17.3 months. Overall, 66% of patients were alive at 1 year.

This problem led Zhang and his colleagues to look for ways to improve outcomes. Because the CASPIAN trial did not include radiation to the primary tumor, it seemed a logical strategy to explore. Six patients had liver metastases at the baseline, and three had brain metastases. Over half had prophylactic cranial radiation. Performance scores were 0-1, and all but one of the participants were men.

Hanna wanted more information on the radiotoxicity issue, but even so, he said that adding low-dose radiation to our durvalumab-chemotherapy doublet warrants further investigation.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Adding Low-Dose Radiation Improves Survival Outcomes in Small Cell Lung CancerA small, single-arm study presented at the 2024 European Lung Cancer Congress suggests that adding low-dose radiation to the standard first-line treatment for extensive-stage small cell lung cancer (SCLC) improves patients' median progression-free and overall survival. The study included 30 patients and showed a higher median progression-free survival of 8.3 months and extended median overall survival beyond the study follow-up period of 17.3 months. These findings are considered promising compared to the results of the 2019 CASPIAN trial.
Source: Medscape - 🏆 386. / 55 Read more »

FDA Approves Ponatinib for Upfront Ph+ ALLThis is the first targeted treatment approved for upfront use in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Source: Medscape - 🏆 386. / 55 Read more »

Study: Colorectal cancer patients could skip harsh radiation therapyA groundbreaking medical study involving the UCSF Medical Center has shown some colorectal cancer patients can safely skip radiation treatment and enjoy a potentially higher quality of life.
Source: KPIXtv - 🏆 443. / 53 Read more »